Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Sangamo Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 09, 2020 / 10:00PM GMT
Release Date Price: $10.43
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Hi everyone, this is Marty Auster. I'm the lead SMID-Cap Biotech Analyst here at Crédit Suisse. I think -- I was mistaken, the last presentation thinking he was the last final one of the day. I believe this is the final presentation of the day.

I am happy to have Sangamo Therapeutics here with us today. I'm going to hand it over now to Sandy Macrae. Thank you, Sandy. Take it away.

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Thank you. So if I can now share my screen. And make it -- there we go. So thank you. And during today's presentation, I'll be making forward-looking statements. So please refer to our latest filings with the SEC.

And we are Sangamo. We're Sangamo Therapeutics, where we're committed to translating groundbreaking science into genomic medicines that transform patients' lives. And all those parts are important. It's about the science. It's about making medicines. And it's about making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot